India Shuns Onglyza Compulsory License But Lee To Fight On?
This article was originally published in Scrip
Executive Summary
India's Controller General of Patents is said to have viewed unfavourably the compulsory license (CL) application for AstraZeneca's Onglyza (saxagliptin) by the Hyderabad-based Lee Pharma, although Lee appears keen to hang on to the challenge.